Exploring Novel Protein Degraders & Maximizing Therapeutic Window in Degrader-Antibody-Conjugates

• Leveraging targeted protein degradation to expand therapeutic reach
• Differentiated MOA compared to existing ADC payloads
• Designing linkers to maximize therapeutic window

Speakers:

Alice Chen

Chief Scientific Officer

Baylink Bioscience